CAVIA is the acronym of “Cerebral Amyloid Angiopathy (CAA): Vascular Imaging and fluid markers of Amyloid deposition”. This project aims at the identification of novel neurochemical biomarkers (in cerebrospinal fluid  or blood) and functional neuroimaging biomarkers (by MRI) for CAA.


Cerebral Amyloid Angiopathy (CAA)

Cerebral Amyloid Angiopathy (CAA) is one of the most prevalent cerebrovascular diseases in the elderly and is characterized by vascular deposition of the amyloid β protein. CAA is increasingly recognized as an important cause of cognitive decline or dementia and of cerebral hemorrhages in old age. It has a high prevalence (10-50% of the general population), which increases with age. Also, approximately 80% of  Alzheimer’s disease patients do have CAA.


The CAVIA project

The CAVIA project is a consortium of the Radboud university medical center (Nijmegen), Leiden university medical center, Erasmus medical center (Rotterdam), VU medical center (Amsterdam), Stony Brook University (New York), Massachusetts General Hospital (Boston), ADX Neurosciences (Gent), and Philips Healthcare (Eindhoven). The CAVIA project is financed by the Deltaplan dementia. The aims of this Deltplam are to prevent and cure dementia, provide better dementia care and a dementia friendly society; both for today’s and tomorrow’s patients.